O
Oncoinvent ASA
OSE:ONCIN
Oncoinvent ASA
OSE:ONCIN
Price:
40.75
NOK
-3.44%
Market Closed
Market Cap:
kr182.6m
Relative Value
The Relative Value of one ONCIN stock under the Base Case scenario is 77.58 NOK. Compared to the current market price of 40.75 NOK, Oncoinvent ASA is Undervalued by 47%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
ONCIN
Relative Value
Base Case
77.58
NOK
Undervaluation 47%
O
Multiples Across Competitors
ONCIN Competitors Multiples
Oncoinvent ASA Competitors
Oncoinvent ASA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| NO |
O
|
Oncoinvent ASA
OSE:ONCIN
|
182.6m NOK | 33.8 | -1.7 | -1 | -1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
952.4B USD | 14.6 | 46.1 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
592.2B USD | 6.3 | 22.1 | 15.3 | 18.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
286.2B CHF | 4.7 | 30.4 | 12.8 | 15 | |
| CH |
|
Novartis AG
SIX:NOVN
|
244.8B CHF | 5.6 | 22.5 | 13.9 | 17.9 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.4B GBP | 5.4 | 30.7 | 17 | 23.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
298.8B USD | 4.6 | 16.4 | 10.1 | 12.4 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.5 | 10.6 | 7.9 | 9.2 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.6B USD | 2.4 | 19.5 | 7.5 | 10 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
125.8B USD | 2.6 | 17.8 | 7.4 | 9.2 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
